| Stage | ESAB | % of rev | NDSN | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $808M | 100.00% | $818M | 100.00% | NDSN ×1.01 |
| Gross profit | $307M | 38.04% | $454M | 55.49% | NDSN +17.5pp |
| Operating income | $79M | 9.75% | $223M | 27.28% | NDSN +17.5pp |
| Pre-tax income | $48M | 5.96% | $186M | 22.74% | NDSN +16.8pp |
| Net income | $34M | 4.21% | $153M | 18.69% | NDSN +14.5pp |
| Stage | ESAB | NDSN | Gap · A − B |
|---|---|---|---|
| Revenue | $808M100.00% | $818M100.00% | NDSN ×1.01 |
| Gross profit | 38.04%$307M | 55.49%$454M | NDSN +17.5pp |
| Operating income | 9.75%$79M | 27.28%$223M | NDSN +17.5pp |
| Pre-tax income | 5.96%$48M | 22.74%$186M | NDSN +16.8pp |
| Net income |
| 4.21%$34M |
| 18.69%$153M |
| NDSN +14.5pp |
No disclosed counterparties: NDSN.
None